The firm reduced the price target to $20 from $30 for the RNA interference (RNAi) therapeutics company.
Leerink reiterated it's "market perform" rating for Tekmira Pharmaceuticals and said it lowered the company's price target to reflect more realistic Ebola profits following 3Q financial results.
Must Read: Warren Buffett's 25 Favorite Stocks
"TKMR faces significant clinical and regulatory risks since its product candidates are currently in early stage preclinical or clinical development," said Leerink analysts Dr. Michael Schmidt and Dr. Jonathan Chang.
Separately, TheStreet Ratings team rates TEKMIRA PHARMACEUTICALS CORP as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate TEKMIRA PHARMACEUTICALS CORP (TKMR) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow."